LDLR and neoplasm: For example, nab‐paclitaxel (albumin‐paclitaxel nanoparticles) showed better efficacy than paclitaxel in some tumors, presumably via targeting the Gp60 transcytosis pathway in endothelial cells and binding to secreted protein, acidic and rich in cysteine (SPARC) in the tumor extracellular matrix.[23] In this work, we uncovered a novel strategy to co‐deliver combination chemotherapies via active targeting of LDLR in tumors.